This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Biological drivers of clinical phenotype in myelofibrosis
Leukemia Open Access 24 November 2022
-
Towards a Personalized Definition of Prognosis in Philadelphia-Negative Myeloproliferative Neoplasms
Current Hematologic Malignancy Reports Open Access 01 September 2022
-
Is there a gender effect in polycythemia vera?
Annals of Hematology Open Access 02 October 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM et al. The 2016 revision to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia. Blood 2016; 127: 2391–2405.
Passamonti F, Thiele J, Girodon F, Rumi E, Carobbio A, Gisslinger H et al. A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. Blood 2012; 120: 1197–1201.
Passamonti F, Rumi E, Pietra D, Elena C, Boveri E, Arcaini L et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia 2010; 24: 1574–1579.
Barosi G, Mesa RA, Thiele J, Cervantes F, Campbell PJ, Verstovsek S et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 2008; 22: 437–438.
Tefferi A, Lasho TL, Finke CM, Knudson RA, Ketterling R, Hanson CH et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia 2014; 28: 1472–1477.
Rotunno G, Pacilli A, Artusi V, Rumi E, Maffioli M, Delaini F et al. Epidemiology and clinical relevance of mutations in post-polycythemia vera and post-essential thrombocythemia myelofibrosis. A study on 359 patients of the AGIMM group. Am J Hematol 2016; 91: 681–686.
Passamonti F, Rumi E, Caramella M, Elena C, Arcaini L, Boveri E et al. A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis. Blood 2008; 111: 3383–3387.
Hernandez-Boluda JC, Pereira A, Gomez M, Boque C, Ferrer-Marin F, Raya JM et al. The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis. Haematologica 2014; 99: e55–e57.
Beauverd Y, Alimam S, McLornan DP, Radia DH, Harrison CN . Disease characteristics and outcomes in younger adults with primary and secondary myelofibrosis. Br J Haematol 2016; 175: 37–42.
Vannucchi AM, Lasho TL, Guglielmelli P, Biamonte F, Pardanani A, Pereira A et al. Mutations and prognosis in primary myelofibrosis. Leukemia 2013; 27: 1861–1869.
Rumi E, Pietra D, Pascutto C, Guglielmelli P, Martinez-Trillos A, Casetti I et al. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood 2014; 124: 1062–1069.
Pietra D, Rumi E, Ferretti VV, Buduo CA, Milanesi C, Cavalloni C et al. Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. Leukemia 2016; 30: 431–438.
Elala YC, Lasho TL, Gangat N, Finke C, Barraco D, Haider M et al. Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia. Am J Hematol 2016; 91: 503–506.
Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011; 29: 392–397.
Finazzi MC, Carobbio A, Cervantes F, Isola IM, Vannucchi AM, Guglielmelli P et al. CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis. Leukemia 2015; 29: 1209–1210.
Acknowledgements
This work was supported by a grant from Associazione Italiana per la Ricerca sul Cancro (AIRC; Milano, Italy), Special Program Molecular Clinical Oncology 5x1000 to AIRC-Gruppo Italiano Malattie Mieloproliferative (AGIMM) project #1005. A complete list of AGIMM investigators is available at http://www.progettoagimm.it Supported also by AIRC IG2014-15967 and by Ministero della Salute (project code GR-2011-02352109) to PG. Varese group was also supported by a grant from the Fondazione Matarelli (Milano, Italy), Fondazione Rusconi (Varese, Italy) and AIL Varese ONLUS.
Author contributions
FP, AMV, MC, BM and MM contributed to the conception of the work; FP, TG and BM contributed to the design of the work; FP, BM, PG, MC, MM, AR, MC, RK, JG, JJK, FC, TD, NV, VDS, MR, RS, GB, FA, DC, ER, MMe, DP, RC, TB, LP and AMV contributed to the acquisition, analysis or interpretation of data for the work; FP, BM, TG, PG, MC, MM, AR, MC, RK, JG, JJK, FC, TD, NV, VDS, MR, RS, GB, FA, DC, ER, MMe, DP, RC, TB, LP and AMV contributed to revising the manuscript critically for important intellectual content and approved the final version of the manuscript; TG was responsible for the statistical analysis.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Passamonti, F., Mora, B., Giorgino, T. et al. Driver mutations’ effect in secondary myelofibrosis: an international multicenter study based on 781 patients. Leukemia 31, 970–973 (2017). https://doi.org/10.1038/leu.2016.351
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2016.351
This article is cited by
-
Biological drivers of clinical phenotype in myelofibrosis
Leukemia (2023)
-
Allogeneic hematopoietic cell transplantation in patients with CALR-mutated myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT
Bone Marrow Transplantation (2023)
-
Towards a Personalized Definition of Prognosis in Philadelphia-Negative Myeloproliferative Neoplasms
Current Hematologic Malignancy Reports (2022)
-
Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients
Leukemia (2022)
-
Is there a gender effect in polycythemia vera?
Annals of Hematology (2021)